Lbp Am Sa Has $10.97 Million Position in Edwards Lifesciences Corporation $EW

Lbp Am Sa grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 502.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 128,702 shares of the medical research company’s stock after buying an additional 107,330 shares during the quarter. Lbp Am Sa’s holdings in Edwards Lifesciences were worth $10,972,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EW. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after acquiring an additional 365,581 shares during the last quarter. Wellington Management Group LLP boosted its position in Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after purchasing an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Jennison Associates LLC grew its stake in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares in the last quarter. Finally, Ninety One UK Ltd increased its position in shares of Edwards Lifesciences by 14.0% during the 3rd quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock worth $615,050,000 after purchasing an additional 969,030 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 86,058 shares of company stock valued at $7,118,636 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Barclays restated an “overweight” rating and set a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Finally, BTIG Research reissued a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.74.

Get Our Latest Research Report on EW

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $78.90 on Friday. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $45.49 billion, a P/E ratio of 43.11, a P/E/G ratio of 2.04 and a beta of 0.95. Edwards Lifesciences Corporation has a 12 month low of $68.63 and a 12 month high of $87.89. The stock has a 50 day moving average of $81.23 and a 200-day moving average of $82.03.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the company posted $0.59 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Featured Stories

• Five stocks we like better than Edwards Lifesciences

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).